Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.

Abstract

Background: Gastric Cancer (GC) represents a highly prevalent and aggressive form of malignancy. Recent scholarly endeavors have implicated the RNA binding motif protein 15 (RBM15) gene in the onset and progression of cancer. The present study was designed to delve into the expression profile of RBM15 in GC, assess its prognostic significance, and explore its potential as a viable therapeutic target.

Methods: In this investigation, we conducted a comprehensive analysis of multiple facets related to the gene RBM15 in GC samples utilizing publicly accessible databases, including TCGA, GEPIA, TIMER, HPA, Kaplan-Meier Plotter, CPADS, and BEST. Specifically, we examined the mRNA expression levels, clinicopathological characteristics, and survival prognosis, conducted gene function enrichment assessments, analyzed mutation profiles, performed immune cell infiltration evaluations, and assessed drug sensitivity. Notably, all parameters employed in the online databases adhered to their respective default settings.

Results: The expression of RBM15 mRNA is upregulated in GC and exhibits a correlation with a favorable prognosis, with an HR of 0.74 (95% CI = 0.62-0.88, p = 0.00054). Specifically, its expression is notably higher in tumor tissues compared to normal tissues. Furthermore, RBM15 expression is associated with differences in pTNM stage, gender, and racial disparities in survival outcomes. Functionally, RBM15 is implicated in DNA replication and cell cycle regulation. Mutations within the RBM15 gene are frequently observed in GC. Additionally, a positive correlation has been identified between RBM15 expression and immune cell infiltration. Drug sensitivity analyses suggest that RBM15 may represent potential therapeutic targets for GC treatment, further highlighting its pivotal role in the progression of GC.

Conclusion: RBM15 mRNA is upregulated in GC and significantly associated with a favorable prognosis. It correlates with clinicopathological features, is enriched in DNA replication processes, and is commonly mutated. Its expression also impacts immune cell infiltration and drug sensitivity, indicating its potential as a prognostic marker and therapeutic target in GC.